Celldex raising over $30M to advance brain cancer vaccine returned by Pfizer
This article was originally published in Scrip
Executive Summary
Celldex Therapeutics, which focuses on targeted immunotherapies, on 18 May priced a secondary public offering of 10 million shares of its common stock at $3.15 per share for proceeds of about $31.5 million, in part to begin planning for a pivotal Phase III study of its investigational brain cancer vaccine rindopepimut as a front-line treatment for gliobastoma multiforme, an aggressive type of brain cancer.